WillItSurvive
Medical technology and health companies · United States

10x Genomics

10xgenomics.com ↗

Makes single-cell and spatial genomics instruments and consumables used in biology labs worldwide.

Defensible for now
Assessed 22 July 2026 · Evidence as of 22 July 2026
Real protection, with named pressure against it.
On the recordSince 22 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: Atera spatial platform ships to first customers (~40 supply-constrained units) and Q2/Q3 2026 earnings show whether guided sequential declines hit
The call

10x Genomics has the patents and installed base to keep rivals at bay, but flat growth and heavy exposure to NIH funding leave its next year riding on Atera's launch and government budgets, not on any AI threat.

10x Genomics sells machines and kits that let scientists see where genes are located inside cells and tissues. The company is hard to replace because it owns patents that competitors like Bruker and Vizgen have already paid it to settle (over $90 million in 2025), and hospitals and research labs are locked in by the equipment they already own. The real threat is not a rival or new AI tool, but whether the US government will keep funding research labs at current levels, since roughly half of 10x's revenue comes from government-sponsored science, and the company already cut staff and froze guidance in May 2025 when that funding tightened.

Why
01
AI pressure: None apparent. AI virtual-cell models are trained on 10x's single-cell data, making AI a customer for its output, not a replacement for it. Could AI do the core job? Unlikely.
02
Bigger players: Bruker and Vizgen (recently paid $68M and $26M in patent settlements) plus Parse Biosciences. Rivals keep launching competing spatial platforms; 10x has won patent fights so far but growth is now flat at 0 to 4 percent guided for 2026. Could a giant copy it? Probably.
03
What protects it. Court-tested patents on spatial genomics plus a large installed base of instruments that lock customers into 10x consumables.
What would change this call
10x ships and reports adoption of Atera platform (~40 units) by Q4 2026. shows whether the new spatial platform executes on time or slips, testing demand-delay thesis.
Q2/Q3 2026 earnings show sequential revenue decline as guided (report due ~August 6, 2026). confirms whether pre-Atera purchase pause is temporary or a deeper demand problem.
NIH/US government research funding levels stabilize or face further cuts in 2026. tests whether the ~40-50% government-funding exposure triggers another guidance withdrawal.
Key numbers
  • FY2025 revenue $598.7M ex-settlement, down ~2% y/y (2025-12-31)
  • 40 to 50% of revenue tied to government research funding (2025-05-19)
  • Cash position $539.8M as of Q1 2026 (2026-03-31)
Named risks
  • 40-50% of revenue tied to US government research funding, already caused 2025 guidance withdrawal. Severity: high
  • Atera platform shipments (~40 units) concentrated and supply-constrained in Q4 2026. Severity: medium
  • FY2026 guidance implies only 0-4% growth, signaling stalled top-line expansion. Severity: medium
  • Ongoing patent litigation with Curio Bioscience could produce adverse rulings. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Bruker Spatial BiologycontestingPaid 10x $68M in May 2025 settlement but continues selling CosMx and GeoMx platforms
VizgencontestingPaid 10x $26M upfront in 2025 patent settlement, still sells MERSCOPE platform
Parse Biosciencesgaining onCustomer benchmark showed 20% higher gene-detection rate versus 10x, reported 2025-03-04
Curio BiosciencecontestingOngoing patent litigation at EU Unified Patent Court as of mid-2025
Questions people ask
Is 10x Genomics profitable in 2026?
10x Genomics guided FY2026 revenue of $600-625M, only 0-4% growth over 2025's $598.7M ex-settlement figure, with Q1 2026 gross margin near 70% and $539.8M cash as of March 31, 2026, but the company has not reported sustained net profitability.
Did 10x Genomics have layoffs?
Yes. On May 19, 2025, 10x Genomics cut about 8% of its workforce (roughly 100 jobs) and withdrew 2025 guidance, citing NIH and USAID funding disruption; a WARN notice confirmed 93 Pleasanton, CA employees affected effective July 2025.
Who is 10x Genomics' biggest competitor?
Bruker Spatial Biology (CosMx, GeoMx platforms) and Vizgen (MERSCOPE) are its closest spatial-genomics rivals; both settled patent litigation with 10x in 2025, paying it $68M and $26M respectively while continuing to compete in the market.
Could AI replace 10x Genomics?
No. 10x's core business is generating physical single-cell and spatial molecular data via lab instruments, which AI cannot substitute; instead AI models like Arc Institute's Virtual Cell Atlas (300M+ cells, April 2025) train on 10x-generated data, making AI a demand tailwind rather than a threat.
What is 10x Genomics' Atera platform and why does it matter?
Atera is a new whole-transcriptome spatial biology platform launched April 18, 2026, priced at $495,000, which CEO Serge Saxonov called the most significant product introduction in company history; about 40 units are expected to ship, mostly in Q4 2026.
Who owns 10x Genomics?
10x Genomics is publicly traded on Nasdaq as TXG since its September 12, 2019 IPO, which raised $390M. BlackRock is the largest disclosed institutional holder (~10M shares); market cap was about $5.99B on July 22, 2026.
Timeline
  • 2026-06-09Acquired Proteintech Genomics division, gaining Human Discovery Panel, absorbing 8 employees
  • 2026-05-07Q1 2026 revenue $150.8M reported; FY2026 guidance held at $600-625M
  • 2026-04-18Launched Atera spatial biology platform, list price $495,000
  • 2025-07-06WARN notice confirms 93 Pleasanton, CA layoffs effective
  • 2025-06-26Arc Institute launched Virtual Cell Challenge with NVIDIA, 10x, Ultima sponsorship
  • 2025-05-19Laid off ~8% of workforce (~100 jobs), withdrew 2025 guidance citing NIH/USAID disruption
  • 2025-05-14Settled patent litigation with Bruker ($68M) and Vizgen ($26M)
  • 2025-04-28Partnered with Arc Institute and Ultima Genomics on Virtual Cell Atlas (300M+ cells)
  • 2019-09-12IPO on Nasdaq, raising $390M
Head to head
10x Genomics vs Singular Genomics10x Genomics vs Vizgen, Inc.
Revision history
22 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
AbridgeSeegeneOlympus Corporation
More in Medical technology and health companies →
Sources